Return
Polycaprolactone-Based scaffolds in osteomyelitis treatment
Y
M
K
M
A
N
M
DOI:10.1016/j.eurpolymj.2026.114972.png)
Abstract
En 中文
Osteomyelitis (OM), is a devastating bone infection that complicated by biofilm forming and multidrug-resistant (MDR) pathogens, remains a clinical challenge due to the limitations of systemic antibiotics and the non-biodegradable nature of threapticual bone cements. This review overviewed the transformative role of polycaprolactone (PCL)-based scaffolds as next-generation, multifunctional delivery systems for overcoming these challenges. We discussed how the intrinsic advantages of PCL, its biocompatibility, tunable mechanical properties, and compatibility with advanced manufacturing like 3D printing, are leveraged to create sophisticated composite systems. The evolution of PCL from primary drug carriers to advanced multifunctional scaffolds is a central theme, highlighting innovations such as controlled drug release, the co-delivery of antimicrobials and osteogenic agents, and the use of combinatorial therapies to eradicate biofilms and overcome microbial resistance. We discussed that PCL-based scaffolds achieve a dual therapeutic effects, providing sustained, localized antimicrobial activity that far exceeds the efficacy of systemic delivery while concurrently acting as an osteoconductive and osteoinductive matrix to promote bone regeneration. Convincing preclinical validation using robust in vivo models, which demonstrates the simultaneous eradication of infection and significant bone healing, highlights the tremendous translational potential of this technology.This review overviewed the potential of PCL-based scaffolds in the management of OM, paving the way for a new standard of care in which a single, biodegradable implant actively regulates the complete healing of OM defects.
Journal
IF:
6.3
Papers:
1.3W
Citations:
3.6W

